BRPI0212266B8 - anticorpos humanizados anti-ccr4, método de produção dos mesmos, medicamento, e agentes terapêuticos e de diagnóstico - Google Patents

anticorpos humanizados anti-ccr4, método de produção dos mesmos, medicamento, e agentes terapêuticos e de diagnóstico

Info

Publication number
BRPI0212266B8
BRPI0212266B8 BRPI0212266A BRPI0212266B8 BR PI0212266 B8 BRPI0212266 B8 BR PI0212266B8 BR PI0212266 A BRPI0212266 A BR PI0212266A BR PI0212266 B8 BRPI0212266 B8 BR PI0212266B8
Authority
BR
Brazil
Prior art keywords
antibody
ccr4
therapeutic
drug
production
Prior art date
Application number
Other languages
English (en)
Inventor
Shimizu Akiko
Hosaka Emi
Nakamura Kazuyasu
Shitara Kenya
Koike Masamichi
Original Assignee
Kyowa Hakko Kirin Co Ltd
Kyowa Kirin Co Ltd
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd, Kyowa Kirin Co Ltd, Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kirin Co Ltd
Publication of BR0212266A publication Critical patent/BR0212266A/pt
Publication of BRPI0212266B1 publication Critical patent/BRPI0212266B1/pt
Publication of BRPI0212266B8 publication Critical patent/BRPI0212266B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)

Abstract

anticorpo enxertado com cdr humano e fragmento de anticorpo do mesmo. anticorpo enxertado com cdr humano ou fragmento de anticorpo do mesmo que especificamente reage com a região extracelular do receptor de quimiocina cc humano (ccr4) mas não reage com uma plaqueta sangüínea humana; um anticorpo enxertado com cdr humano ou fragmento de anticorpo do mesmo que especificamente reage com a região extracelular de ccr4 e tem atividade citotóxica contra uma célula expressando ccr4; e um medicamento, um agente terapêutico ou um agente de diagnóstico compreendendo pelo menos um dos anticorpos e seus fragmentos de anticorpo como um ingrediente ativo.
BRPI0212266 2001-08-31 2002-08-30 anticorpos humanizados anti-ccr4, método de produção dos mesmos, medicamento, e agentes terapêuticos e de diagnóstico BRPI0212266B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001265144 2001-08-31
PCT/JP2002/008828 WO2003018635A1 (en) 2001-08-31 2002-08-30 Human cdr-grafted antibodies and antibody fragments thereof

Publications (3)

Publication Number Publication Date
BR0212266A BR0212266A (pt) 2004-10-19
BRPI0212266B1 BRPI0212266B1 (pt) 2020-05-05
BRPI0212266B8 true BRPI0212266B8 (pt) 2021-05-25

Family

ID=19091652

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0212266 BRPI0212266B8 (pt) 2001-08-31 2002-08-30 anticorpos humanizados anti-ccr4, método de produção dos mesmos, medicamento, e agentes terapêuticos e de diagnóstico

Country Status (23)

Country Link
US (8) US7504104B2 (pt)
EP (1) EP1449850B9 (pt)
JP (1) JP4052515B2 (pt)
KR (1) KR100959248B1 (pt)
CN (1) CN100430420C (pt)
AT (1) ATE490277T1 (pt)
AU (1) AU2002338015B8 (pt)
BE (1) BE2019C006I2 (pt)
BR (1) BRPI0212266B8 (pt)
CA (1) CA2458627C (pt)
CO (1) CO5560582A2 (pt)
CY (2) CY1111193T1 (pt)
DE (1) DE60238503D1 (pt)
DK (1) DK1449850T3 (pt)
ES (1) ES2356190T3 (pt)
FR (1) FR19C1028I2 (pt)
HK (1) HK1073851A1 (pt)
LU (1) LUC00116I2 (pt)
MX (1) MXPA04001894A (pt)
NL (1) NL300985I2 (pt)
NO (1) NO334858B1 (pt)
PT (1) PT1449850E (pt)
WO (1) WO2003018635A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
EP1992644A1 (en) * 2000-03-03 2008-11-19 Kyowa Hakko Kogyo Co., Ltd Antibodies against CCR4 and its fragments
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2003072134A1 (fr) * 2002-02-28 2003-09-04 Kyowa Hakko Kogyo Co., Ltd. Diagnostics et therapeutiques pour la pneumonie interstitielle
WO2003084569A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
EP1698640B2 (en) 2003-10-01 2019-06-19 Kyowa Hakko Kirin Co., Ltd. Method of stabilizing antibody and stabilized solution-type antibody preparation
JPWO2005035582A1 (ja) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 Ｃｃｒ４に特異的に結合する抗体組成物
ATE486611T1 (de) * 2003-12-04 2010-11-15 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
HUE064610T2 (hu) 2003-12-23 2024-04-28 Genentech Inc Új anti-IL 13 antitestek és alkalmazásaik
US20060034841A1 (en) * 2004-06-07 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Method of depleting regulatory T cell
CA2597717C (en) * 2005-02-18 2014-10-21 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
US20070172476A1 (en) * 2005-07-28 2007-07-26 Kyowa Hakko Kogyo Co., Ltd. Method of treating B-cell neoplasms or Hodgkin's lymphoma
US20080118978A1 (en) 2006-04-28 2008-05-22 Takashi Sato Anti-tumor agent
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
WO2009086514A1 (en) * 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
JP5552630B2 (ja) * 2008-10-24 2014-07-16 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−ｉ関連脊髄症を治療または予防するための医薬、およびｈｔｌｖ−ｉ関連脊髄症の患者に対する抗体療法の効果を試験する方法
GB0909906D0 (en) * 2009-06-09 2009-07-22 Affitech As Antibodies
WO2011030841A1 (ja) 2009-09-10 2011-03-17 協和発酵キリン株式会社 ヒトｃｃケモカイン受容体４（ｃｃｒ４）に特異的に結合する抗体組成物を含む医薬
CN102863533B (zh) * 2010-06-21 2013-12-11 中国科学技术大学 抗体人源化改造方法
CA2807673A1 (en) 2010-08-10 2012-02-16 Xinyi Cynthia Chen Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
NZ713202A (en) 2010-12-16 2017-12-22 Genentech Inc Diagnosis and treatments relating to th2 inhibition
EP3626739A1 (en) 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
BR112015000068A2 (pt) 2012-07-06 2017-08-08 Kyowa Hakko Kirin Co Ltd método terapêutico e medicamento para mielopatia associada a htlv-1 (ham)
KR102571391B1 (ko) 2013-09-13 2023-08-29 제넨테크, 인크. 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
WO2015038884A2 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
CN106413751A (zh) 2014-05-21 2017-02-15 辉瑞大药厂 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
KR20180025897A (ko) 2015-07-14 2018-03-09 교와 핫꼬 기린 가부시키가이샤 항체와 조합 투여되는 ido 억제제를 포함하는 종양 치료제
WO2017220990A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
KR20200098590A (ko) * 2017-12-12 2020-08-20 마크로제닉스, 인크. 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도
CN108250290B (zh) * 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 Ccr4的n端重组蛋白及其用途
CN116731186B (zh) * 2023-07-07 2023-12-26 武汉爱博泰克生物科技有限公司 抗人IgG-Fc兔单克隆抗体及其制备方法、多核苷酸分子、表达载体和宿主细胞

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH0853355A (ja) 1994-08-12 1996-02-27 Taisho Pharmaceut Co Ltd Ｉｌ−５産生抑制剤
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
KR100259828B1 (ko) 1995-09-11 2000-06-15 히라타 다다시 인체 인터루킨 5 수용체 알파-사슬에 대한 항체
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
DE69835441T2 (de) 1997-11-12 2007-08-02 F. Hoffmann-La Roche Ag Behandlung von t-helfer zell typ 2 vermittelten immunkrankheiten mit retinoid antagonisten
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
PL345117A1 (en) 1998-06-26 2001-12-03 Chugai Pharmaceutical Co Ltd Remedies for hypercalcemic crisis
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
EP1050307A1 (en) 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 antagonists in sepsis
EP1992644A1 (en) * 2000-03-03 2008-11-19 Kyowa Hakko Kogyo Co., Ltd Antibodies against CCR4 and its fragments
ATE486611T1 (de) * 2003-12-04 2010-11-15 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament

Also Published As

Publication number Publication date
EP1449850A4 (en) 2005-08-10
CY1111193T1 (el) 2015-06-11
LUC00116I2 (pt) 2019-12-27
DE60238503D1 (de) 2011-01-13
US10131711B2 (en) 2018-11-20
BR0212266A (pt) 2004-10-19
US20150315285A1 (en) 2015-11-05
FR19C1028I1 (pt) 2019-05-17
CA2458627A1 (en) 2003-03-06
US8143058B2 (en) 2012-03-27
CY2019022I2 (el) 2019-11-27
US7504104B2 (en) 2009-03-17
US20110059524A1 (en) 2011-03-10
PT1449850E (pt) 2011-02-02
BE2019C006I2 (pt) 2021-11-22
HK1073851A1 (en) 2005-10-21
US20140186349A1 (en) 2014-07-03
AU2002338015B2 (en) 2008-02-07
MXPA04001894A (es) 2005-09-08
WO2003018635A1 (en) 2003-03-06
US8900584B2 (en) 2014-12-02
KR20040044492A (ko) 2004-05-28
US10590203B2 (en) 2020-03-17
US20180030146A1 (en) 2018-02-01
EP1449850B1 (en) 2010-12-01
AU2002338015B8 (en) 2008-03-20
DK1449850T3 (da) 2011-02-14
FR19C1028I2 (fr) 2021-02-19
US20130273038A1 (en) 2013-10-17
LUC00116I1 (pt) 2019-05-02
NL300985I2 (en) 2019-11-21
CO5560582A2 (es) 2005-09-30
CA2458627C (en) 2013-09-10
ATE490277T1 (de) 2010-12-15
KR100959248B1 (ko) 2010-05-26
NO20040976L (no) 2004-06-01
US20090227012A1 (en) 2009-09-10
JP4052515B2 (ja) 2008-02-27
ES2356190T3 (es) 2011-04-05
CN100430420C (zh) 2008-11-05
JPWO2003018635A1 (ja) 2004-12-09
BRPI0212266B1 (pt) 2020-05-05
EP1449850B9 (en) 2011-05-11
US9051371B2 (en) 2015-06-09
US20030175273A1 (en) 2003-09-18
NL300985I1 (en) 2019-05-08
CY2019022I1 (el) 2019-11-27
NO334858B1 (no) 2014-06-23
EP1449850A1 (en) 2004-08-25
CN1575303A (zh) 2005-02-02
US7842797B2 (en) 2010-11-30
US20120177643A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
BRPI0212266B8 (pt) anticorpos humanizados anti-ccr4, método de produção dos mesmos, medicamento, e agentes terapêuticos e de diagnóstico
Kovarik et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation
Lonial et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma
Hanna et al. A phase II study of methylphenidate for the treatment of fatigue
NO332893B1 (no) Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi
Caimi et al. The antiCD19 antibody drug immunoconjugate loncastuximab achieves responses in DLBCL relapsing after antiCD19 CAR-T cell therapy
BRPI0511755A (pt) composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
WO2004050016A3 (en) Delivery of pharmaceutical agents via the human insulin receptor
DE60138867D1 (de) Medikament zum Schutz gegen thrombotische Krankheiten
Tøttrup et al. Continuous versus short-term infusion of cefuroxime: assessment of concept based on plasma, subcutaneous tissue, and bone pharmacokinetics in an animal model
Bose et al. Management of myelofibrosis after ruxolitinib failure
BR112022003811A2 (pt) Tratamento de retinopatia diabética com fab anti vegf totalmente humano modificado pós tradução
ES2080037T1 (es) Medicamento de uso topico con actividad cicatrizante.
Stjernschantz et al. Effect of latanoprost on regional blood flow and capillary permeability in the monkey eye
DE50111328D1 (de) SGK3 ALS DIAGNOSTISCHEs UND THERAPEUTISCHEs TARGET
NO985571L (no) Legemiddel for autoimmunsykdommer
Chandra et al. Test‐dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non‐malignant disorders
Price et al. Intracranial phycomycosis: a clinicopathological and radiological study
Hoffstedt et al. Penetration of ceftazidime into extracellular fluid in patients
Chow et al. Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once‐daily doses
WO1998032429A3 (en) P2 receptor agonists, antagonists and modulators of endogenous atp release for the treatment of skin conditions and the improvement of wound healing
Trinquand et al. Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study
ITRM960755A1 (it) Composizione disinfettante in particolare per la prevenzione di derma titi da pannolini e metodo per la sua utilizzazione
Ryan et al. Oral candidosis in the paediatric patient
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: KYOWA HAKKO KIRIN CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: KYOWA HAKKO KIRIN CO., LTD. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: KYOWA KIRIN CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: KYOWA KIRIN CO., LTD. (JP)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/05/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/08/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 30/08/2022